Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial
Year: 2008
Type: article
Source: Blood
Institutions: Royal Brompton Hospital, University College London, University of Milan, Chinese University of Hong Kong, Prince of Wales Hospital, Ege University, University Malaya Medical Centre, National and Kapodistrian University of Athens, Novartis (United States), Novartis (Switzerland), American University of Beirut
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2554014150